N-of-One's advisory board includes some of the world's leading experts in oncology, cancer biology and evidence-based medicine, as well as seasoned biotech and high-tech entrepreneurs.

Ask an N-of-One cancer treatment strategist a question now.

President, CEO & Chief Scientific Officer, Targeted Molecular Diagnostics, LLC
Sarah Bacus founded Targeted Molecular Diagnostics in January of 2004. In addition, Dr. Bacus had previously founded Quantitative Diagnostics Laboratories and co-founded Cell Analysis Systems, both of which were successfully acquired by established diagnostic companies. Dr. Bacus pioneered the quantitative image analysis processes of tissue-based cellular diagnostics and is currently regarded as a world-renown expert on targeted therapy and diagnostics development.

She is the author of numerous patents and peer-reviewed publications covering cell biology, diagnostics and systems development. Dr. Bacus has, for more than two decades, been a prolific researcher and lecturer in the field of cancer, and specifically, targeted therapy. Dr. Bacus is a frequent speaker at international oncology symposiums such as the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR) and the European Organization for Research and Treatment of Cancer (EORTC).

In addition to the roles above, Dr. Bacus has served the industry in other advisory and operational roles. These appointments include adjunct faculty positions at M.D. Anderson Cancer Center and a board seat of the prestigious Cancer Research Foundation, an organization dedicated to funding Phase I clinical trials. Dr. Bacus has also taken on several consulting roles with diagnostics technology and information technology companies.

Director, Ludwig Center at the Dana-Farber/ Harvard Cancer Center; Quick Family Senior Investigator in Medical Oncology, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School
Dr. Demetri received an undergraduate degree in biochemistry from Harvard University, followed by a Rotary Foundation Fellowship at the Universite de Besancon, France. In 1983, he received his medical degree from Stanford University School of Medicine, California, USA. After completing internal medicine residency and chief residency at the University of Washington Hospitals in Seattle, Washington, he pursued a fellowship in medical oncology at the Dana-Farber Cancer Institute (DFCI) and Harvard Medical School, where he has served as an attending physician since 1989. Trained in the DFCI laboratory of James D. Griffin in molecular biology of hematopoietic cytokines, Dr. Demetri began his clinical and translational research career as an investigator in the application of recombinant human hematopoietic growth factors as an adjunct to anticancer chemotherapy for sarcomas and other solid tumors. Dr. Demetri and his colleagues then developed a large research-focused multidisciplinary center of excellence for sarcoma patients at the Dana-Farber/Brigham and Women's Hospital Cancer Center, which actively pursues translational and clinical research for sarcomas and other connective tissue neoplasms. Dr. Demetri's research and clinical interests have focused on mechanism-based drug development for solid tumors, with a particular emphasis on molecularly-defined subsets of sarcomas such as Gastrointestinal Stromal Tumors (GIST). Work from the multidisciplinary team at Dana-Farber/Harvard has contributed to the development of imatinib (Gleevec), sunitinib (Sutent), trabectedin (Yondelis) and other new pathway-targeted therapies in development. Dr. Demetri serves as co-chair of the Medical Advisory Board for the Sarcoma Foundation of America and is a member of the Executive Committee of the Sarcoma Alliance for Research through Collaboratoin (SARC). With an interest in internet-based patient support, he also serves on the Medical Advisory Board of the patient-focused site for the American Society of Clinical Oncology (www.cancer.net), prior to which he had founded a nonprofit patient education website (www.sarcoma.net). In 2005, he was appointed Director of the Ludwig Center at the Dana-Farber/Harvard Cancer Center, which supports novel research in cell signaling and other translational science initiatives relevant to cancer across multiple departments of Harvard University.

Founder, Personal Physicians HealthCare in Chestnut Hill, Massachusetts
Dr. Flier has been a practicing primary care physician in Boston since 1979. A graduate of the City College of New York and the Albert Einstein College of Medicine, his postdoctoral training (internship, residency and nephrology fellowship) were all completed at Brigham and Women's Hospital in Boston. He has been on the faculty of Harvard Medical School since 1979, where he is currently Assistant Clinical Professor of Medicine, and a Senior Fellow of the Oliver Wendell Holmes Society. From 1992 through 2001 he held positions as Vice Chairman of the Department of Medicine, Chief of the Division of Community Medicine at Beth Israel Deaconess Medical Center, and CEO of the Affiliated Physicians Group, where he was responsible for the creation and operation of a 90 physician primary care network of Harvard faculty physicians, with 25 sites throughout the greater Boston area. During these years he developed major interests in quality and service improvement, doctor-patient communication, and error reduction through the use of electronic medical records. He has served as a faculty member for the Institute of Healthcare Improvement and has lectured nationally in these areas. In 2001, Dr. Flier left his hospital positions, and together with his partners Drs. Jordan Busch and Nancy Corliss opened Personal Physicians HealthCare, a primary-care practice designed to provide the highest quality service and attention to a limited number of patients, funded by annual patient fees in addition to insurance premiums. Physicians HealthCare has been featured in front page stories in the New York Times, Washington Post and Boston Globe, and in interviews and reports on NBC's Today Show.

Physician, Massachusetts General Hospital ( M.G.H.) and Clinical Professor of Medicine, Harvard Medical School, and Professor of Medicine, Tufts University
Dr. Gelfand has served as Dean for Research at Tufts University School of Medicine, Professor and Chairman of the Department of Medicine at Tufts and Physician-in-Chief at the New England Medical Center. He is now at M.G.H. pursuing his passion for developing new therapeutics. Dr. Gelfand has conducted laboratory and clinical research in immunology, inflammation, infection, and more recently, tumor immunology. He has developed two therapies for immune diseases that remain standard for over two decades. He has applied his background in immunology and immunotherapy to the field of vaccines for infectious diseases and cancer therapeutics. Most recently, he has developed a novel monoclonal-based, fusion- protein vaccine platform.

Professor of Medicine and Professor of Clinical Research at the Institute for Clinical Research and Health Policy Studies, Tufts-New England Medical Center; and Adjunct Professor at the Friedman School of Nutrition Science and Policy
Dr. Lau has directed the AHRQ designated Evidence-based Practice Center at the Tufts-NEMC since 1997. From 1996 to beginning of 2007, he also directed the Boston Branch of the US Cochrane Center. He serves as Program Director, Evidence-based Medicine, of the Evidence Review Team in the National Kidney Foundation's clinical practice guidelines program, since 2000. He has published over 200 articles and book chapters in the clinical applications and methodological issues in areas of systematic review, meta-analysis, evidence-based medicine and development of clinical practice guidelines. He has led the production of over 50 AHRQ evidence reports and technology assessments. He has served on FDA advisory panel, IOM committee and as a drafting expert on an FAO/WHO workgroup. He is a member of the editorial board of Clinical Evidence and is an advisor on medical research methodology to Biomed Central. Dr. Lau was elected as a member of the Association of American Physicians in 2006.

Professor of Pathology and Laboratory Medicine and Molecular and Medical Pharmacology, UCLA School of Medicine and Scientific Director, UCLA Sarkaria Biomarkers program
Dr. Mischel is a Professor of Pathology & Laboratory Medicine and Molecular & Medical Pharmacology at the David Geffen UCLA School of Medicine. He obtained his M.D. from Cornell University Medical College in 1991. Following residency in Anatomic Pathology and Fellowship in Neuropathology at UCLA, Dr. Mischel did his post- doctoral research training with Dr. Louis F. Reichardt at the Howard Hughes Medical Institute at UCSF. Dr. Mischel's laboratory is focused on molecularly targeted therapies for brain cancer and on the development of quantitative molecular approaches to help identify the individual patients most likely to benefit. His research involves examining mechanisms of targeted pathway inhibitor sensitivity and resistance and using this information to develop molecularly guided combination therapies, using systems biology approaches to find and test new drug targets, and integrating new diagnostic technologies to guide cancer treatment. Dr. Mischel and colleagues have identified molecular determinants of response to EGFR kinase inhibitors in glioblastoma patients and begun to identify potential combination strategies to overcome resistance. Dr. Mischel is the recipient of a number of awards including the Farber Award, and he was recently elected to a three-year term (vice-president 2008-9, president-elect 2009-10, and president (20010-11) for the American Society for Clinical Investigation.

Vice President of Drug Development Partnerships, Quintiles Transnational
In his current position at Quintiles Transnational, the leading CRO supporting drug development throughout the globe, Dr. Smith works closely with pharmaceutical and biotech companies to create successful programs for cancer drug development and use with a focus on personalized medicine. Previously, Dr. Smith led Corporate Development at Cell Signaling Technology, a leading biotechnology company in the life sciences field. His previous positions at Cell Signaling Technology include management of antibody and clinical assay development departments. Previous to Cell Signaling Technology, Dr. Smith directed antibody development and production at Santa Cruz Biotechnology, helping to build that company into the largest supplier of antibodies for basic research. Dr. Smith's scientific background includes research positions at Stanford University and University of California, San Francisco focused on cellular signaling mechanisms of disease. Dr. Smith holds a doctoral degree from Stanford University and masters and bachelors degrees from University of California, Santa Cruz.

Erving Professor of Chemistry, Harvard University; Executive Director of the Dana-Farber Chemical Biology Initiative
Dr. Verdine is a research leader in the emerging area of chemical biology. He and his co-workers study biologic processes underlying control of gene expression and preservation of genomic integrity. He has made major contributions to the understanding of DNA damage recognition and repair by base-excision DNA repair enzymes. He has also pioneered new and powerful approaches for the discovery of unconventional bioactive ligands for receptors that have proven difficult to target with conventional drugs. Dr. Verdine received his B.S. degree in 1982 from St. Joseph's University and his Ph.D. in 1986 from Columbia University (under Koji Nakanishi and Maria Tomasz). Following an NIH postdoctoral fellowship with Chris Walsh at M.I.T. and Harvard Medical School, he joined the Harvard University Department of Chemistry in 1988. Dr. Verdine was promoted to Full Professor in 1994 and was also named Harvard College Professor in 2000. In 2002, he was named the Erving Professor of Chemistry, the longest-established endowed professorship at Harvard. He is a Full Member of the Harvard Department of Molecular and Cellular Biology, and co-directs two graduate programs, the University-wide Graduate Program in Chemical Biology (co-founded with Jon Clardy) and the Graduate Program in Molecular, Cellular and Chemical Biology. Together with Stanley J. Korsmeyer, Dr. Verdine co-founded and is the Executive Director of the Harvard/Dana-Farber Program in Cancer Chemical Biology. He has published more than 150 original research articles, and has received numerous awards and honors, including the National Science Foundation Presidential Young Investigator Award, the Sloan Fellowship, the Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, the Arthur C. Cope Scholar Award, the Nucleic Acids Award of the Royal Society of Chemistry, the Cruikshank Award of the Gordon Research Conferences, and the Nobel Laureate Signature Award of the American Chemical Society (with Anirban Banerjee). He currently serves as Founder and Chair of the Scientific Advisory Boards of Enanta Pharmaceuticals, Aileron Therapeutics, and Gloucester Pharmaceuticals, and is a Special Advisor to the Texas Pacific Group.